IL144519A0 - 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use - Google Patents
16-halogen-epothilone derivatives, method for producing them and their pharmaceutical useInfo
- Publication number
- IL144519A0 IL144519A0 IL14451900A IL14451900A IL144519A0 IL 144519 A0 IL144519 A0 IL 144519A0 IL 14451900 A IL14451900 A IL 14451900A IL 14451900 A IL14451900 A IL 14451900A IL 144519 A0 IL144519 A0 IL 144519A0
- Authority
- IL
- Israel
- Prior art keywords
- halogen
- producing
- pharmaceutical use
- epothilone derivatives
- epothilone
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19908765A DE19908765A1 (de) | 1999-02-18 | 1999-02-18 | 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| DE19954230A DE19954230A1 (de) | 1999-11-04 | 1999-11-04 | 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| PCT/EP2000/001333 WO2000049021A2 (de) | 1999-02-18 | 2000-02-18 | 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144519A0 true IL144519A0 (en) | 2002-05-23 |
Family
ID=26052117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14451900A IL144519A0 (en) | 1999-02-18 | 2000-02-18 | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US6610736B1 (xx) |
| EP (1) | EP1150980B1 (xx) |
| JP (1) | JP2002537301A (xx) |
| KR (1) | KR100718616B1 (xx) |
| CN (1) | CN1209360C (xx) |
| AR (1) | AR022636A1 (xx) |
| AT (1) | ATE370946T1 (xx) |
| AU (1) | AU3156700A (xx) |
| BG (1) | BG105802A (xx) |
| BR (1) | BR0008331A (xx) |
| CA (1) | CA2361278A1 (xx) |
| CZ (1) | CZ20012951A3 (xx) |
| DE (1) | DE50014587D1 (xx) |
| EA (1) | EA009206B1 (xx) |
| EE (1) | EE200100431A (xx) |
| ES (1) | ES2291194T3 (xx) |
| HK (1) | HK1044945A1 (xx) |
| HR (1) | HRP20010677A2 (xx) |
| HU (1) | HUP0105478A3 (xx) |
| IL (1) | IL144519A0 (xx) |
| MX (1) | MXPA01008328A (xx) |
| NO (1) | NO20014013L (xx) |
| NZ (1) | NZ513268A (xx) |
| PL (1) | PL349863A1 (xx) |
| SK (1) | SK11852001A3 (xx) |
| TW (1) | TWI285645B (xx) |
| WO (1) | WO2000049021A2 (xx) |
| YU (1) | YU59001A (xx) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ303422B6 (cs) | 1996-11-18 | 2012-09-05 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP1386922B1 (en) | 1996-12-03 | 2012-04-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| DE59814067D1 (de) * | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| US6518421B1 (en) * | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
| DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| AU2002245296B2 (en) * | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
| IL156580A0 (en) | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog |
| ES2304240T3 (es) | 2001-01-25 | 2008-10-01 | Bristol-Myers Squibb Company | Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer. |
| BR0207316A (pt) | 2001-02-20 | 2004-02-10 | Bristol Myers Squibb Co | Derivados de epotilona para o tratamento de tumores refratários |
| BR0207487A (pt) | 2001-02-20 | 2004-08-10 | Brystol Myers Squibb Company | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona |
| RU2321400C2 (ru) | 2001-03-14 | 2008-04-10 | Бристол-Маерс Сквибб Компани | Композиция аналога эпотилона в сочетании с химиотерапевтическими агентами для лечения рака |
| JP2004532888A (ja) | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
| WO2003026744A1 (en) * | 2001-09-25 | 2003-04-03 | Alcon, Inc. | The use of epothilones and analogs in conjunction with ophthalmic surgery |
| EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
| AU2003218110A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
| WO2003077903A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| WO2003105828A1 (en) | 2002-06-14 | 2003-12-24 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| RU2311415C2 (ru) * | 2002-08-23 | 2007-11-27 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения |
| DK1506203T3 (da) * | 2002-08-23 | 2007-05-14 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoger deraf og anvendelser deraf |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| MXPA05003006A (es) | 2002-09-23 | 2005-06-22 | Squibb Bristol Myers Co | Metodos para la preparacion, aislamiento y purificacion de epotilona b y estructuras cristalinas de rayos x y de epotilona b. |
| EP1559447A1 (en) | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
| BRPI0518286A2 (pt) * | 2004-11-18 | 2008-11-11 | Bristol Myers Squibb Co | microesfera com revestimento entÉrico contendo ixabepilona e sua preparaÇço |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| WO2007086879A2 (en) | 2005-02-11 | 2007-08-02 | University Of Southern California | Method of expressing proteins with disulfide bridges |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| US20070014978A1 (en) * | 2005-07-18 | 2007-01-18 | Anthony Poloso | Method of flame blocking and articles made therefrom |
| EP2029156A4 (en) * | 2006-05-01 | 2010-07-21 | Univ Southern California | POLY THERAPY FOR TREATING CANCER |
| CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
| EP2065054A1 (en) * | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
| DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
| EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
| WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
| EP2534170B1 (en) | 2010-02-12 | 2017-04-19 | Pharmascience Inc. | Iap bir domain binding compounds |
| US9764038B2 (en) | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
| WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2685521B2 (ja) | 1988-08-05 | 1997-12-03 | 株式会社日立製作所 | 車両用換気装置 |
| EP0353732A3 (de) * | 1988-08-05 | 1991-11-06 | Ciba-Geigy Ag | Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung |
| ZW20390A1 (en) * | 1989-12-27 | 1991-06-19 | Monsanto Co | Substituted pyridine compounds |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| DE59814067D1 (de) * | 1997-08-09 | 2007-09-06 | Bayer Schering Pharma Ag | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| WO2000000485A1 (de) * | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
-
2000
- 2000-02-18 EA EA200100826A patent/EA009206B1/ru unknown
- 2000-02-18 CZ CZ20012951A patent/CZ20012951A3/cs unknown
- 2000-02-18 IL IL14451900A patent/IL144519A0/xx unknown
- 2000-02-18 EP EP00909205A patent/EP1150980B1/de not_active Expired - Lifetime
- 2000-02-18 CN CNB008039763A patent/CN1209360C/zh not_active Expired - Fee Related
- 2000-02-18 NZ NZ513268A patent/NZ513268A/en unknown
- 2000-02-18 YU YU59001A patent/YU59001A/sh unknown
- 2000-02-18 US US09/913,495 patent/US6610736B1/en not_active Expired - Fee Related
- 2000-02-18 WO PCT/EP2000/001333 patent/WO2000049021A2/de not_active Application Discontinuation
- 2000-02-18 KR KR1020017010455A patent/KR100718616B1/ko not_active IP Right Cessation
- 2000-02-18 MX MXPA01008328A patent/MXPA01008328A/es active IP Right Grant
- 2000-02-18 JP JP2000599760A patent/JP2002537301A/ja active Pending
- 2000-02-18 HU HU0105478A patent/HUP0105478A3/hu unknown
- 2000-02-18 EE EEP200100431A patent/EE200100431A/xx unknown
- 2000-02-18 BR BR0008331-3A patent/BR0008331A/pt not_active Application Discontinuation
- 2000-02-18 AT AT00909205T patent/ATE370946T1/de not_active IP Right Cessation
- 2000-02-18 SK SK1185-2001A patent/SK11852001A3/sk unknown
- 2000-02-18 DE DE50014587T patent/DE50014587D1/de not_active Expired - Fee Related
- 2000-02-18 ES ES00909205T patent/ES2291194T3/es not_active Expired - Lifetime
- 2000-02-18 PL PL00349863A patent/PL349863A1/xx not_active Application Discontinuation
- 2000-02-18 CA CA002361278A patent/CA2361278A1/en not_active Abandoned
- 2000-02-18 AU AU31567/00A patent/AU3156700A/en not_active Abandoned
- 2000-02-21 AR ARP000100714A patent/AR022636A1/es unknown
- 2000-04-19 TW TW089102834A patent/TWI285645B/zh not_active IP Right Cessation
-
2001
- 2001-08-09 BG BG105802A patent/BG105802A/bg unknown
- 2001-08-17 NO NO20014013A patent/NO20014013L/no not_active Application Discontinuation
- 2001-09-14 HR HR20010677A patent/HRP20010677A2/hr not_active Application Discontinuation
-
2002
- 2002-09-03 HK HK02106485A patent/HK1044945A1/xx not_active IP Right Cessation
-
2003
- 2003-02-12 US US10/364,337 patent/US6930102B2/en not_active Expired - Fee Related
-
2005
- 2005-03-25 US US11/090,841 patent/US20050187270A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL349863A1 (en) | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use | |
| HUP0201711A3 (en) | N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them | |
| HK1046681A1 (en) | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use | |
| HUP0202472A3 (en) | Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments | |
| HUP0000748A2 (en) | 4-phenyl-piridine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0203425A3 (en) | Quinazoline derivatives, process for their preparation and their use | |
| HUP0301333A3 (en) | Pharmaceutical superdisintegrant, process for its preparation and its use | |
| HUP0302295A3 (en) | Thienodibenzoazulene derivatives, process for their preparation and use thereof | |
| PL350190A1 (en) | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals | |
| AU3156600A (en) | Novel epothilon derivatives, method for the production thereof and their pharmaceutical application | |
| HUP0103316A3 (en) | 2-ureido-pyrimidone derivatives, method for producing them, pharmaceutical compositions containing them and their use | |
| HUP0105479A3 (en) | Betha-alanine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HUP0201552A2 (en) | Quaternary ammonium derivatives, method for preparing the same and their pharmaceutical use | |
| HUP0201916A2 (en) | Ethanesulfonyl-piperidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| IL145041A (en) | Morpholine derivatives, methods for the production thereof and pharmaceutical preparations | |
| AU2796602A (en) | Coniosetin and derivatives thereof, method for producing the same and use thereof | |
| HUP0203443A3 (en) | Novel contraceptive medicament and method for producing the same | |
| HUP0203468A3 (en) | Betha-d-5-thioxylose derivatives, preparation method and therapeutic use thereof | |
| ZA9810403B (en) | New epothilon derivatives, process for their preparation and their pharmaceutical use. | |
| EP1172442A4 (en) | VITAMIN D DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | |
| AU7517800A (en) | 3-vinylpyrrole derivatives, method for the production thereof and their use as medicaments | |
| IL156160A0 (en) | Klainetins and their derivatives, method for their preparation and use thereof | |
| HUP0204393A3 (en) | Pluraflavins and derivatives thereof, process for their preparation and use thereof | |
| SI1230252T1 (en) | Beta-d-5-thioxylose derivatives, preparation method and therapeutic use | |
| SI1175428T1 (en) | 3-deoxy-desmycosin derivatives and process for their preparation |